Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks - - New hormonal ...
Eli Lilly's retatrutide cut breathing interruptions and drove significant weight loss in sleep apnea patients, as well as ...
Nxera Pharma Co. Ltd. announced that it has exercised its option to license lucerastat from Idorsia Ltd. and has entered into a co-development and commercialization agreement (the "Agreement"). Under ...
Caregiving is such a universal task, faced by nearly all of us at one time or another. The following stress-reducing ...
Hello. This is Seien.This time, I would like to focus on Solfeggio frequencies. You may often see the title "Solfeggio ...
Iroko Psychiatry offers adults in Mansfield personalized depression care, psychiatric evaluations, and treatment ...
FAB-KLEAR investigates lucerastat as a potential disease-modifying therapy targeting the kidney manifestations of Fabry disease. Nxera will contribute to development and hold commercialization rights ...
We continue ‘Your Monthly Check-Up’ — with a look at sleep apnea. If you’re constantly tired — even after a full night’s ...
When sleep apnea is diagnosed through polysomnography, CPAP therapy is usually recommended. The problem is that many patients ...
The Trump administration is pushing to dramatically expand veterans' access to psychedelic drugs as potential treatments for ...
During Menopause Awareness Month, Femelle Gynecology and Wellness backs new ACOG guidance naming hormone therapy for hot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results